Mineralys Therapeutics, Inc.
MLYSNasdaq
$27.09
↑ +0.0%Jul 17 close · end-of-day
Price
1Y↑ +89.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.2B
Enterprise Value
$2.1B
P/E
—
P/S
—
P/B
3.5
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$151.8M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-23.8%
ROIC
-25.8%
Debt / Equity
—
Net Cash
$112.8M
Return 1Y
+88.9%
Company profile
We are a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. We were originally founded as a Delaware corporation on May 31, 2019 under the name Catalys SC1, Inc. On May 29, 2020, we changed our name to Mineralys Therapeutics, Inc. Our principal executive offices are located at 150 N. Radnor Chester Road, Suite F200, Radnor, PA.
- CEO
- Jon Congleton
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- Pennsylvania
- Website
- mineralystx.com
Management & directors
- Rodman David MalcomChief Medical Officer
- Congleton JonChief Executive Officer
- Warren EricChief Commercial Officer
- Levy Adam ScottCFO and Secretary
Roles derived from SEC Form 4 filings.
Earnings
MLYS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.47↓ -40.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$31.5M | -$84.7M | -$192.4M | -$170.6M |
| Net income | -$29.8M | -$71.9M | -$177.8M | -$154.7M |
| Diluted EPS | -$5.77 | -$1.99 | -$3.66 | -$2.29 |
| Operating cash flow | -$29.2M | -$81.2M | -$166.3M | -$142.4M |
| Free cash flow | — | — | — | — |
| Gross margin | — | — | — | — |
| Operating margin | — | — | — | — |
| Net margin | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$45.2M | -$60.1M | -$51.8M | -$44.4M | -$46.7M | -$41.1M | -$38.3M | -$45.3M |
| Net income | -$41.0M | -$56.3M | -$48.9M | -$42.2M | -$43.3M | -$36.9M | -$32.2M | -$39.3M |
| Diluted EPS | -$0.83 | -$1.13 | -$1.00 | -$0.79 | -$0.66 | -$0.52 | -$0.32 | -$0.47 |
| Operating cash flow | -$30.1M | -$50.2M | -$66.8M | -$45.5M | -$30.2M | -$28.9M | -$37.9M | -$39.5M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 16, 2026
Jun 23, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-15 | Rodman David Malcom· Chief Medical Officer | Sale | 6,349 | $26.61 | $168,954.51 | filing |
| 2026-07-13 | Rodman David Malcom· Chief Medical Officer | Sale | 14,058 | $27.58 | $387,716.83 | filing |
| 2026-07-13 | Congleton Jon· Chief Executive Officer | Sale | 10,700 | $27.24 | $291,441.25 | filing |
| 2026-07-13 | Rodman David Malcom· Chief Medical Officer | Option exercise | 4,167 | $14.25 | $59,379.75 | filing |
| 2026-07-13 | Rodman David Malcom· Chief Medical Officer | Option exercise | 3,542 | $10.20 | $36,128.40 | filing |
| 2026-07-13 | Rodman David Malcom· Chief Medical Officer | Option exercise | 6,349 | $1.08 | $6,856.92 | filing |
| 2026-07-09 | Rodman David Malcom· Chief Medical Officer | Sale | 2,171 | $30.30 | $65,781.30 | filing |
| 2026-07-09 | Rodman David Malcom· Chief Medical Officer | Option exercise | 2,171 | $16.00 | $34,736.00 | filing |
| 2026-06-30 | Congleton Jon· Chief Executive Officer | Sale | 58,000 | $25.94 | $1.5M | filing |
| 2026-06-30 | Congleton Jon· Chief Executive Officer | Sale | 17,000 | $26.82 | $455,895.80 | filing |
| 2026-06-26 | Warren Eric· Chief Commercial Officer | Sale | 104,124 | $25.90 | $2.7M | filing |
| 2026-06-26 | Warren Eric· Chief Commercial Officer | Option exercise | 104,124 | $13.24 | $1.4M | filing |
| 2026-06-17 | Rodman David Malcom· Chief Medical Officer | Sale | 4,584 | $25.00 | $114,600.00 | filing |
| 2026-06-17 | Karydas Daphne | Sale | 3,000 | $25.00 | $75,000.00 | filing |
| 2026-06-17 | Rodman David Malcom· Chief Medical Officer | Option exercise | 4,167 | $14.25 | $59,379.75 | filing |
| 2026-06-17 | Karydas Daphne | Option exercise | 3,000 | $12.02 | $36,060.00 | filing |
| 2026-06-17 | Rodman David Malcom· Chief Medical Officer | Option exercise | 417 | $15.44 | $6,438.48 | filing |
| 2026-06-15 | Rodman David Malcom· Chief Medical Officer | Sale | 9,890 | $23.81 | $235,486.83 | filing |
| 2026-06-15 | Rodman David Malcom· Chief Medical Officer | Option exercise | 3,542 | $10.20 | $36,128.40 | filing |
| 2026-06-12 | Rodman David Malcom· Chief Medical Officer | Sale | 6,349 | $23.93 | $151,901.09 | filing |
| 2026-06-12 | Rodman David Malcom· Chief Medical Officer | Option exercise | 6,349 | $1.08 | $6,856.92 | filing |
| 2026-06-10 | Rodman David Malcom· Chief Medical Officer | Sale | 2,170 | $25.00 | $54,250.00 | filing |
| 2026-06-10 | Rodman David Malcom· Chief Medical Officer | Option exercise | 2,170 | $16.00 | $34,720.00 | filing |
| 2026-05-18 | Rodman David Malcom· Chief Medical Officer | Sale | 417 | $27.55 | $11,488.35 | filing |
| 2026-05-18 | Rodman David Malcom· Chief Medical Officer | Option exercise | 417 | $15.44 | $6,438.48 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.